[go: up one dir, main page]

MX2019006519A - Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. - Google Patents

Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.

Info

Publication number
MX2019006519A
MX2019006519A MX2019006519A MX2019006519A MX2019006519A MX 2019006519 A MX2019006519 A MX 2019006519A MX 2019006519 A MX2019006519 A MX 2019006519A MX 2019006519 A MX2019006519 A MX 2019006519A MX 2019006519 A MX2019006519 A MX 2019006519A
Authority
MX
Mexico
Prior art keywords
methods
systems
botulinum neurotoxin
purifying non
complexed botulinum
Prior art date
Application number
MX2019006519A
Other languages
English (en)
Inventor
L Ruegg Curtis
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43879799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019006519(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of MX2019006519A publication Critical patent/MX2019006519A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan métodos y sistemas para la purificación cromatográfica de una neurotoxina botulínica. Estos métodos y sistemas permiten la purificación eficiente de la forma no acomplejada de la neurotoxina botulínica en un alto grado de pureza y rendimiento que pueda usarse como ingrediente activo en preparaciones farmacéuticas.
MX2019006519A 2009-10-21 2012-04-20 Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. MX2019006519A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25381009P 2009-10-21 2009-10-21

Publications (1)

Publication Number Publication Date
MX2019006519A true MX2019006519A (es) 2019-09-18

Family

ID=43879799

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012004703A MX2012004703A (es) 2009-10-21 2010-10-20 Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
MX2015011592A MX365496B (es) 2009-10-21 2010-10-20 Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
MX2019006519A MX2019006519A (es) 2009-10-21 2012-04-20 Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012004703A MX2012004703A (es) 2009-10-21 2010-10-20 Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
MX2015011592A MX365496B (es) 2009-10-21 2010-10-20 Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.

Country Status (24)

Country Link
US (5) US20110092682A1 (es)
EP (1) EP2490986B2 (es)
JP (1) JP5951490B2 (es)
KR (1) KR101819129B1 (es)
CN (2) CN102666396B (es)
AU (1) AU2010310749B2 (es)
BR (1) BR112012009227A2 (es)
CA (1) CA2773396C (es)
CO (1) CO6551670A2 (es)
CY (1) CY1120908T1 (es)
DK (1) DK2490986T4 (es)
ES (1) ES2688065T5 (es)
HR (1) HRP20181869T1 (es)
HU (1) HUE041599T2 (es)
IL (2) IL218532A (es)
LT (1) LT2490986T (es)
MX (3) MX2012004703A (es)
PH (1) PH12012500549A1 (es)
PL (1) PL2490986T3 (es)
PT (1) PT2490986T (es)
RS (1) RS58006B1 (es)
SI (1) SI2490986T1 (es)
SM (1) SMT201800487T1 (es)
WO (1) WO2011050072A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800215T1 (it) 2008-12-31 2018-05-02 Revance Therapeutics Inc Formulazioni iniettabili di tossina botulinica domanda di brevetto correlata
KR101975051B1 (ko) * 2009-06-25 2019-05-03 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
PT2490986T (pt) * 2009-10-21 2018-11-13 Revance Therapeutics Inc Métodos e sistemas para purificar neurotoxina botulínica não complexada
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
AU2014298922B2 (en) * 2013-07-30 2018-03-15 Merz Pharma Gmbh & Co. Kgaa Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
KR102903132B1 (ko) 2018-12-21 2025-12-23 시오노기세이야쿠가부시키가이샤 보툴리누스 독소의 제조 방법
KR102447441B1 (ko) * 2019-04-15 2022-09-27 (주)제테마 보툴리눔 독소의 정제방법
KR102485146B1 (ko) * 2019-04-15 2023-01-06 (주)제테마 보툴리눔 독소의 제조방법
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
KR102724650B1 (ko) * 2021-07-05 2024-11-01 주식회사 파마리서치바이오 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법
KR102724651B1 (ko) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102512757B1 (ko) * 2021-07-22 2023-03-22 (주)이니바이오 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법
EP4682254A1 (en) * 2023-03-16 2026-01-21 Daewoong Co., Ltd. Improved method of purifying botulinum toxin using multimodal chromatography
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
DE102025101336A1 (de) 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse
KR20250178368A (ko) * 2024-06-19 2025-12-29 (주)제테마 클로스트리디움 보툴리눔 독소의 정제방법

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US796419A (en) 1904-07-18 1905-08-08 Carl Halbig Doll-head.
SE303567B (es) * 1959-02-17 1968-09-02 Behringwerke Ag
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
WO1999037326A1 (en) * 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9921592D0 (en) * 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AU8466501A (en) * 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
GB2386246B (en) 2001-11-01 2005-06-29 Marconi Applied Techn Ltd Electron beam tube apparatus
DE60335602D1 (de) * 2002-12-18 2011-02-17 Roche Diagnostics Gmbh Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
KR100498964B1 (ko) 2003-03-05 2005-07-01 삼성전자주식회사 이동단말에서의 전자파 흡수율 제어 방법 및 장치
WO2004108750A1 (en) * 2003-06-06 2004-12-16 Avecia Limited Process for the separation of proteins
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
AU2004309177A1 (en) * 2003-12-30 2005-07-14 Bharat Biotech International Limited A process for the preparation and purification of recombinant proteins
KR20050074806A (ko) * 2004-01-14 2005-07-19 팜텍(주) 결정형 보툴리늄 독소의 제조방법
CA2558408C (en) * 2004-03-03 2014-11-18 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8974774B2 (en) * 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
MXPA06009853A (es) * 2005-03-03 2007-03-29 Allergan Inc Medios para bacteria de clostridium y procesos para obtener una toxina clostridial.
WO2006133818A1 (de) * 2005-06-17 2006-12-21 Merz Pharma Gmbh & Co. Kgaa Vorrichtung und verfahren zur fermentativen herstellung biologisch wirksamer verbindungen
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
JP5634675B2 (ja) * 2006-10-27 2014-12-03 一般財団法人化学及血清療法研究所 乳児ボツリヌス症原因菌由来の高度精製ａ型ボツリヌス毒素製剤
CN100588706C (zh) * 2007-04-06 2010-02-10 常州千红生化制药股份有限公司 纯化弹性蛋白酶的方法
JP2010528999A (ja) * 2007-06-01 2010-08-26 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ボツリヌストキシンの神経毒成分に基づいた、温度安定な筋弛緩薬を固体形態で供給する方法
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
SMT201800215T1 (it) * 2008-12-31 2018-05-02 Revance Therapeutics Inc Formulazioni iniettabili di tossina botulinica domanda di brevetto correlata
US8440204B2 (en) * 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
KR101975051B1 (ko) * 2009-06-25 2019-05-03 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
US8440104B2 (en) * 2009-10-21 2013-05-14 General Electric Company Kimzeyite garnet phosphors
PT2490986T (pt) * 2009-10-21 2018-11-13 Revance Therapeutics Inc Métodos e sistemas para purificar neurotoxina botulínica não complexada
US20150204884A1 (en) * 2012-06-01 2015-07-23 Momenta Pharmaceuticals, Inc. Methods of evaluating and making biologics
WO2014066916A2 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
SG11201803566TA (en) * 2015-10-29 2018-05-30 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
EP3624819A4 (en) * 2017-05-18 2021-03-24 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia

Also Published As

Publication number Publication date
CO6551670A2 (es) 2012-10-31
IL248486A0 (en) 2016-12-29
CN102666396B (zh) 2015-05-13
EP2490986A4 (en) 2013-11-13
SMT201800487T1 (it) 2019-01-11
IL218532A0 (en) 2012-07-31
US20150322419A1 (en) 2015-11-12
HRP20181869T1 (hr) 2019-01-11
US20200277591A1 (en) 2020-09-03
JP5951490B2 (ja) 2016-07-13
MX365496B (es) 2019-06-05
KR20120099431A (ko) 2012-09-10
US20170029795A1 (en) 2017-02-02
US20110092682A1 (en) 2011-04-21
CY1120908T1 (el) 2019-12-11
US9469849B2 (en) 2016-10-18
ES2688065T5 (es) 2024-10-04
PL2490986T3 (pl) 2019-03-29
CN102666396A (zh) 2012-09-12
DK2490986T4 (da) 2024-06-17
LT2490986T (lt) 2018-11-26
RS58006B1 (sr) 2019-02-28
KR101819129B1 (ko) 2018-02-28
CN104961812A (zh) 2015-10-07
JP2013508388A (ja) 2013-03-07
AU2010310749A1 (en) 2012-03-29
HK1175453A1 (en) 2013-07-05
HUE041599T2 (hu) 2019-05-28
CA2773396C (en) 2020-12-15
US11466262B2 (en) 2022-10-11
AU2010310749B2 (en) 2016-02-11
CA2773396A1 (en) 2011-04-28
EP2490986A1 (en) 2012-08-29
BR112012009227A2 (pt) 2016-08-23
US20120196349A1 (en) 2012-08-02
EP2490986B2 (en) 2024-04-24
MX2012004703A (es) 2012-06-08
SI2490986T1 (sl) 2018-12-31
EP2490986B1 (en) 2018-08-08
PH12012500549A1 (en) 2017-08-23
DK2490986T3 (en) 2018-11-05
PT2490986T (pt) 2018-11-13
HK1215951A1 (zh) 2016-09-30
ES2688065T3 (es) 2018-10-30
WO2011050072A1 (en) 2011-04-28
IL218532A (en) 2016-10-31
CN104961812B (zh) 2019-08-20

Similar Documents

Publication Publication Date Title
MX2019006519A (es) Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
WO2013078170A8 (en) Purification of anti-c-met antibodies
IL216466B (en) Compositions for respiratory delivery of active agents and associated methods and systems
MX2020009978A (es) Proceso y sistema para obtener neurotoxina botulinica.
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
IL220219A0 (en) Rna preparations comprising purified modified rna for reprogramming cells
MY187874A (en) Antibody formulations
WO2012065102A8 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
JO3326B1 (ar) مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
MX2009009439A (es) Estabilizacion de vitamina b12.
MX2012003951A (es) Preparacion farmceutica que comprende hcg recombinante.
MX2012007873A (es) Promotor de reparacion del daño de acido desoxirribonucleico para aplicacion oral e inhibidor de la actividad de elastasa para apalicacion oral.
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
MY160372A (en) Composition for improving brain function and method for improving brain function
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
MX390369B (es) Inhibidores tripeptidicos de la epoxicetona proteasa
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
WO2012062685A3 (en) Pharmaceutical composition for treating hcv infections
AU2024266827A1 (en) RNA preparations comprising purified modified RNA for reprogramming cells
MY169877A (en) Treatment of malphigia coccigera on liver cirrhosis
CA2864049A1 (en) Use of beta-nerve growth factor for inducing ovulation in mammals
MY184940A (en) Lignosus rhinocerus (tiger-milk mushroom) as anti-inflammatory agent
UA69686U (ru) Способ профилактики обострений параноидной шизофрении
WO2008017000A3 (en) Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy